Inclusion body myositis in an older patient


  • Olayinka A. Ogundipe Department of Medicine of the Elderly, Royal Infirmary of Edinburgh, Edinburgh, Scotland
  • Vevak Dherwani Department of Medicine of the Elderly, Royal Infirmary of Edinburgh, Edinburgh, Scotland



Chronic disease, Inclusion body myositis, Myopathy, Myositis, Older adult, Sporadic myositis


Inclusion body myositis (IBM) is a condition also referred to as sporadic IBM. It is a rare variant of a broader group of diseases described under the banner of inflammatory myositis. In general, myositis/myositides tend to present with a varying cluster of symptoms such as muscular weakness, aches and/or pain. Myositis has been linked to multiple causes or triggers, but generally share the common feature (present to a variable extent) of inflammatory changes within skeletal muscle tissue. In addition, some associations (e.g. Sjogren’s disease and systemic lupus erythematosus – SLE) have been reported for IBM. Some medication classes (e.g. statins and fibrates) may present a risk to certain individuals developing drug-associated myopathies. IBM can be challenging to diagnose, and may be mistaken for many other causes of muscle weakness e.g. polymyositis. Furthermore, IBM tends to affect muscles asymmetrically, and runs a typically progressive and chronic course. Consequently, over time IBM may result in significant functional impairment, activity limitation, and participation restriction. This case report describes an older woman with a clinical diagnosis of probable IBM complicated with oesophageal dysmotility. She presented to hospital with progressive dysphagia, breathlessness, and a productive cough for which treatment was started for aspiration pneumonia. The report considers some broader ‘principles of management’ of a chronic myositis. In the current absence of a definitive curative treatment, we also discuss some realistic and practical pharmacological treatment options that may be used for the selective care of patients presenting with an incurable chronic myositis such as IBM.

Author Biographies

Olayinka A. Ogundipe, Department of Medicine of the Elderly, Royal Infirmary of Edinburgh, Edinburgh, Scotland

Consultant Physician,

Department of Medicine of the Elderly,

Royal Infirmary of Edinburgh,

EH16 4SA


Vevak Dherwani, Department of Medicine of the Elderly, Royal Infirmary of Edinburgh, Edinburgh, Scotland

Specialty Doctor,
Department of Medicine of the Elderly,
Royal Infirmary of Edinburgh,
EH16 4SA


Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018;14(5):269-78.

Chinoy H, Lilleker JB. Pitfalls in the diagnosis of myositis. Best Pract Res Clin Rheumatol. 2020;34:101486.

McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14(5):290-302.

Betteridge Z, McHugh N. Myositis‐specific autoantibodies: an important tool to support diagnosis of myositis. J Int Med. 2016;280(1):8-23.

Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opinion Rheumatol. 2012;24(6):602-8.

Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, et al. Long-term observational study of sporadic inclusion body myositis. Brain (London, England: 1878). 2011;134(11):3176-84.

Greenberg SA. Inclusion body myositis. Curr Opinion Rheumatol. 2011;23(6):574-8.

Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019;15(5):257-72.

Dimachkie MM, Barohn RJ. Inclusion body myositis. Curr Neurol Neuroscience Rep. 2013;13(1):321.

Benjamin Larman H, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73(3):408-18.

Pluk H, van Hoeve BJA, van Dooren SHJ, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73(3):397-407.

Limaye VS, Cash K, Smith C, Koszyca B, Patel S, Greenberg SA, et al. Inclusion‐body myositis and primary Sjögren syndrome: mechanisms for shared etiologies. Muscle Nerve. 2020;61(5):570-4.

Tasca G, Monforte M, De Fino C, Kley RA, Ricci E, Mirabella M. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve. 2015;52(6):956-62.

Dieudonné Y, Allenbach Y, Benveniste O, Leonard-Louis S, Hervier B, Mariampillai K, et al. Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis. Neurology. 2020;94(9):910-20.

Ogundipe OA, Joshi A, Jones HE. Oculobulbar Myasthenia Gravis in an Octogenerian. J Med Cases. 2013;4(6):433-8.

Zhang H, Charmchi Z, Seidman RJ, Anziska Y, Velayudhan V, Perk J. COVID‐19–associated myositis with severe proximal and bulbar weakness. Muscle Nerve. 2020;62(3):57-60.

Narayanappa G, Nandeesh BN. Infective myositis. Brain pathology (Zurich, Switzerland). 2021;31(3):e12950.

Campbell A, Ogundipe OA. Neuromyelitis optica spectrum disorder presenting in an octogenarian. BMJ Case Rep. 2018;225601.

Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, et al. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021;96(12):1595-607.

British National Formulary. National Institute for Health & Care Excellence. © NICE 2022. Available at: Accessed on 16 June 2022.




How to Cite

Ogundipe, O. A., & Dherwani, V. (2022). Inclusion body myositis in an older patient. International Journal of Basic & Clinical Pharmacology, 11(5), 470–476.